~~<i id='93BBF3A1DA'><strike id='93BBF3A1DA'><tt id='93BBF3A1DA'><pre id='93BBF3A1DA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：fashion 2025-09-27 23:53:36 - browse：8469

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

focus

hotspot

focus

AdobeAtfirstglance,theCoalitionforHealthAIlookslikeanytechnologylobbyinggroup.Itsmembership—includin

WSS

Medicare Advantage enrollment grows 7.1% to 33.4 million people

As AI regulations shape up, health tech startups beg for clarity

A new approach to psychiatric drug development

Elevance, SCAN deals highlight health insurer acquisition scrutiny

In 'major milestone,' FDA approves first cell therapy for solid tumors

State of the Union pitch: Bigger Medicare drug price negotiations

focus

hotspot

focus

How one medical school became remarkably diverse

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Apple is now the first public company to be valued at $3 trillion

Surprise medical billing ban raises prices elsewhere

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Medicare details structure of new drug price negotiation program

Why Talkspace is targeting Medicare, a tricky market

hotspot

First over

A new drug could help frostbite victims avoid its ravages

The public health thinking behind the CDC’s new Covid guidance

MD Anderson's Padmanee Sharma responds to research credit suit

The public health thinking behind the CDC’s new Covid guidance

Immune cells and nerve overgrowth may explain recurring UTI pain

hotspot

hotspot

focus

focus